J
Jessica M. Molkentine
Researcher at University of Texas MD Anderson Cancer Center
Publications - 34
Citations - 670
Jessica M. Molkentine is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Cancer & Pancreatic cancer. The author has an hindex of 12, co-authored 28 publications receiving 517 citations. Previous affiliations of Jessica M. Molkentine include University of Pittsburgh & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
MK-1775, a novel wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells
Kathleen Bridges,Hiroshi Hirai,Carolyn A. Buser,Colin Brooks,Huifeng Liu,Thomas A. Buchholz,Jessica M. Molkentine,Kathryn A. Mason,Raymond E. Meyn +8 more
TL;DR: It is indicated that p53-defective human tumor cells are significantly radiosensitized by the potent and selective wee1 kinase inhibitor, MK-1775, in both the in vitro and in vivo settings.
Journal ArticleDOI
Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer
Meifang Yu,Nicholas D. Nguyen,Yanqing Huang,Daniel Lin,Tara N. Fujimoto,Jessica M. Molkentine,Amit Deorukhkar,Ya'an Kang,F. Anthony San Lucas,Conrad J. Fernandes,Eugene J. Koay,Sonal Gupta,Haoqiang Ying,Albert C. Koong,Joseph M. Herman,Jason B. Fleming,Anirban Maitra,Cullen M. Taniguchi +17 more
TL;DR: Evidence is presented that normalizing the fragmented mitochondria of pancreatic cancer via the process of mitochondrial fusion reduces OXPHOS, which correlates with suppressed tumor growth and improved survival in preclinical models, and that mitochondrial fusion is a specific and druggable regulator of Pancreatic cancer growth that could be rapidly translated to the clinic.
Journal ArticleDOI
Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways
Uma Raju,Oliver Riesterer,Zhi Qiang Wang,David Molkentine,Jessica M. Molkentine,Faye M. Johnson,Faye M. Johnson,Bonnie S. Glisson,Luka Milas,K. Kian Ang +9 more
TL;DR: It is demonstrated that dasatinib induces apoptosis and blocks DNA repair in EGFR-expressing HNSCC cells and improves radiotherapy outcome, and warrant further investigation using in vivo tumor models for potential translation into clinical testing.
Journal ArticleDOI
Use of the LQ model with large fraction sizes results in underestimation of isoeffect doses
Tommy Sheu,Jessica M. Molkentine,Mark K. Transtrum,Thomas A. Buchholz,H. R. Withers,Howard D. Thames,Kathryn A. Mason +6 more
TL;DR: The LQ model underestimates doses for isoeffective crypt-cell survival with large fraction sizes (in the present setting, >9 Gy); the RS model results were consistent with the observed asymmetry.
Journal ArticleDOI
TRIP12 as a mediator of human papillomavirus/p16-related radiation enhancement effects.
Li E. Wang,Peijing Zhang,David Molkentine,C-L Chen,Jessica M. Molkentine,Hai-long Piao,Hai-long Piao,Uma Raju,Jinsong Zhang,David Valdecanas,Ramesh C. Tailor,Howard D. Thames,Thomas A. Buchholz,Jack S.K. Chen,Li Ma,Kathryn A. Mason,K. Kian Ang,Raymond E. Meyn,Heath D. Skinner +18 more
TL;DR: Findings reveal that p16 participates in radiosensitization through influencing DDR and support the rationale of blocking TRIP12 to improve radiotherapy outcomes.